153 related articles for article (PubMed ID: 34265182)
1. Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged-Release Ketamine With Emphasis on 2,6-Hydroxynorketamines.
Weiss M; Siegmund W
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):194-206. PubMed ID: 34265182
[TBL] [Abstract][Full Text] [Related]
2. Chiral LC-MS/MS method for the simultaneous determination of (R,S)-ketamine, (R,S)-norketamine, and (2R,6R;2S,6S)-hydroxynorketamine in mouse plasma and brain.
Toki H; Yamaguchi JI; Mizuno-Yasuhira A; Endo H
J Pharm Biomed Anal; 2023 Feb; 224():115168. PubMed ID: 36473323
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.
Zhao X; Venkata SL; Moaddel R; Luckenbaugh DA; Brutsche NE; Ibrahim L; Zarate CA; Mager DE; Wainer IW
Br J Clin Pharmacol; 2012 Aug; 74(2):304-14. PubMed ID: 22295895
[TBL] [Abstract][Full Text] [Related]
4. Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats.
Moaddel R; Sanghvi M; Ramamoorthy A; Jozwiak K; Singh N; Green C; O'Loughlin K; Torjman M; Wainer IW
J Pharm Biomed Anal; 2016 Aug; 127():3-8. PubMed ID: 27017097
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis.
Kamp J; Jonkman K; van Velzen M; Aarts L; Niesters M; Dahan A; Olofsen E
Br J Anaesth; 2020 Nov; 125(5):750-761. PubMed ID: 32838982
[TBL] [Abstract][Full Text] [Related]
6. Sex-dependent metabolism of ketamine and (
Highland JN; Farmer CA; Zanos P; Lovett J; Zarate CA; Moaddel R; Gould TD
J Psychopharmacol; 2022 Feb; 36(2):170-182. PubMed ID: 34971525
[TBL] [Abstract][Full Text] [Related]
7. The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats.
Moaddel R; Sanghvi M; Dossou KS; Ramamoorthy A; Green C; Bupp J; Swezey R; O'Loughlin K; Wainer IW
Pharmacol Res Perspect; 2015 Aug; 3(4):e00157. PubMed ID: 26171236
[TBL] [Abstract][Full Text] [Related]
8. Quantitative chiral and achiral determination of ketamine and its metabolites by LC-MS/MS in human serum, urine and fecal samples.
Hasan M; Hofstetter R; Fassauer GM; Link A; Siegmund W; Oswald S
J Pharm Biomed Anal; 2017 May; 139():87-97. PubMed ID: 28279931
[TBL] [Abstract][Full Text] [Related]
9. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.
Moaddel R; Abdrakhmanova G; Kozak J; Jozwiak K; Toll L; Jimenez L; Rosenberg A; Tran T; Xiao Y; Zarate CA; Wainer IW
Eur J Pharmacol; 2013 Jan; 698(1-3):228-34. PubMed ID: 23183107
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ketamine and three metabolites in Beagle dogs under sevoflurane vs. medetomidine comedication assessed by enantioselective capillary electrophoresis.
Sandbaumhüter FA; Theurillat R; Bektas RN; Kutter APN; Bettschart-Wolfensberger R; Thormann W
J Chromatogr A; 2016 Oct; 1467():436-444. PubMed ID: 27485149
[TBL] [Abstract][Full Text] [Related]
11. Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects.
Hasan M; Modess C; Roustom T; Dokter A; Grube M; Link A; Rey H; Adler S; Meissner K; Siegmund W
Anesthesiology; 2021 Aug; 135(2):326-339. PubMed ID: 34019627
[TBL] [Abstract][Full Text] [Related]
12. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
[TBL] [Abstract][Full Text] [Related]
13. Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine.
Lilius TO; Viisanen H; Jokinen V; Niemi M; Kalso EA; Rauhala PV
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):481-488. PubMed ID: 29171155
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
Chen BK; Luna VM; LaGamma CT; Xu X; Deng SX; Suckow RF; Cooper TB; Shah A; Brachman RA; Mendez-David I; David DJ; Gardier AM; Landry DW; Denny CA
Neuropsychopharmacology; 2020 Aug; 45(9):1545-1556. PubMed ID: 32417852
[TBL] [Abstract][Full Text] [Related]
15. (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.
Paul RK; Singh NS; Khadeer M; Moaddel R; Sanghvi M; Green CE; O'Loughlin K; Torjman MC; Bernier M; Wainer IW
Anesthesiology; 2014 Jul; 121(1):149-59. PubMed ID: 24936922
[TBL] [Abstract][Full Text] [Related]
16. Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2
Highland JN; Morris PJ; Konrath KM; Riggs LM; Hagen NR; Zanos P; Powels CF; Moaddel R; Thomas CJ; Wang AQ; Gould TD
ACS Chem Neurosci; 2022 Feb; 13(4):510-523. PubMed ID: 35113535
[TBL] [Abstract][Full Text] [Related]
17. Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.
Shirayama Y; Hashimoto K
Int J Neuropsychopharmacol; 2018 Jan; 21(1):84-88. PubMed ID: 29155993
[TBL] [Abstract][Full Text] [Related]
18. Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.
Can A; Zanos P; Moaddel R; Kang HJ; Dossou KS; Wainer IW; Cheer JF; Frost DO; Huang XP; Gould TD
J Pharmacol Exp Ther; 2016 Oct; 359(1):159-70. PubMed ID: 27469513
[TBL] [Abstract][Full Text] [Related]
19. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (
Highland JN; Morris PJ; Zanos P; Lovett J; Ghosh S; Wang AQ; Zarate CA; Thomas CJ; Moaddel R; Gould TD
J Psychopharmacol; 2019 Jan; 33(1):12-24. PubMed ID: 30488740
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL
Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
